Technical Analysis for GHRS - GH Research PLC

Grade Last Price % Change Price Change
B 20.8 -0.43% -0.09
GHRS closed down 0.43 percent on Wednesday, August 4, 2021, on 48 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical GHRS trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Doji - Bearish? Reversal 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Reached Overbought Strength -0.43%
Wide Bands Range Expansion -0.43%
Overbought Stochastic Strength -0.43%
Up 3 Days in a Row Strength -0.43%
Older End-of-Day Signals for GHRS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 19 hours ago
Up 3% about 19 hours ago
Upper Bollinger Band Resistance about 21 hours ago
Rose Above Upper Bollinger Band about 21 hours ago
Down 1% about 21 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression N N Dimethyltryptamine Psychiatric And Neurological Disorders

Is GHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 26.91
52 Week Low 15.08
Average Volume 124,605
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 18.43
10-Day Moving Average 18.50
Average True Range 2.23
ADX 9.88
+DI 24.36
-DI 12.80
Chandelier Exit (Long, 3 ATRs) 15.20
Chandelier Exit (Short, 3 ATRs) 21.78
Upper Bollinger Bands 21.38
Lower Bollinger Band 15.47
Percent B (%b) 0.9
BandWidth 32.04
MACD Line -0.21
MACD Signal Line -0.70
MACD Histogram 0.4852
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.22
Resistance 3 (R3) 23.31 22.61 22.81
Resistance 2 (R2) 22.61 21.99 22.56 22.68
Resistance 1 (R1) 21.70 21.61 22.16 21.61 22.54
Pivot Point 21.00 21.00 21.22 20.95 21.00
Support 1 (S1) 20.09 20.38 20.55 20.00 19.06
Support 2 (S2) 19.39 20.00 19.34 18.92
Support 3 (S3) 18.48 19.39 18.79
Support 4 (S4) 18.39